Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00212108
Status:
COMPLETED
Last Update Posted:
2012-04-02
First Post:
2005-09-13
Brief Title:
A Study Of Nasopharyngeal Carcinoma NPC Treated With Celecoxib And ZD1839
Sponsor:
National University Hospital Singapore
Organization:
National University Hospital Singapore
Study Overview
Official Title:
A Study Of Nasopharyngeal Carcinoma NPC Treated With Celecoxib And ZD1839
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
EGFR and COX-2 are involved in tumorigenesis angiogenesis and metastases and are frequently over expressed in NPCCOX-2 and EGFR inhibitors are active in NPCThere is synergistic action between COX-2 and EGFR inhibitors
Study hypothesis Celecoxib and gefitinib can reduce angiogenesis and induce anti-tumorigenicity in patients with nasopharngeal cancer
Study hypothesis Celecoxib and gefitinib can reduce angiogenesis and induce anti-tumorigenicity in patients with nasopharngeal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None